Back to Search Start Over

The role of an integrated referral program for patients with liver disease: A network between hub and spoke centers

Authors :
Germani, Giacomo
Ferrarese, Alberto
D’Arcangelo, Francesca
Russo, Francesco Paolo
Senzolo, Marco
Gambato, Martina
Zanetto, Alberto
Cillo, Umberto
Feltracco, Paolo
Persona, Paolo
Serra, Eugenio
Feltrin, Giuseppe
Carretta, Giovanni
Capizzi, Alfio
Donato, Daniele
Tessarin, Michele
Burra, Patrizia
Source :
United European Gastroenterology Journal; February 2024, Vol. 12 Issue: 1 p76-88, 13p
Publication Year :
2024

Abstract

Access to Liver transplantation (LT) can be affected by several barriers, resulting in delayed referral and increased risk of mortality due to complications of the underlying liver disease. To assess the clinical characteristics and outcomes of patients with acute or chronic liver disease referred using an integrated referral program. An integrated referral program was developed in 1 October 2017 based on email addresses and a 24/7 telephone availability. All consecutive adult patients with liver disease referred for the first time using this referral program were prospectively collected until 1 October 2021. Characteristics and outcomes of inpatients were compared with a historical cohort of patients referred without using the integrated referral program (1 October 2015—1 October 2017). Patients were further divided according to pre‐ and post‐Covid‐19 pandemic. Two hundred eighty‐one referred patients were considered. End stage liver disease was the most common underlying condition (79.3%), 50.5% of patients were referred as inpatients and 74.7% were referred for LT evaluation. When inpatient referrals (n= 142) were compared with the historical cohort (n= 86), a significant increase in acute liver injury due to drugs/herbals and supplements was seen (p= 0.01) as well as an increase in End stage liver disease due to alcohol‐related liver disease and NASH, although not statistically significant. A significant increase in referrals for evaluation for Trans‐jugular intrahepatic portosystemic shunt placement was seen over time (5.6% vs. 1%; p= 0.01) as well as for LT evaluation (84.5% vs. 81%; p= 0.01). Transplant‐free survival was similar between the study and control groups (p= 0.3). The Covid‐19 pandemic did not affect trends of referrals and patient survival. The development of an integrated referral program for patients with liver disease can represent the first step to standardize already existing referral networks between hub and spoke centers. Future studies should focus on the timing of referral according to different etiologies to optimize treatment options and outcomes.

Details

Language :
English
ISSN :
20506406 and 20506414
Volume :
12
Issue :
1
Database :
Supplemental Index
Journal :
United European Gastroenterology Journal
Publication Type :
Periodical
Accession number :
ejs65453207
Full Text :
https://doi.org/10.1002/ueg2.12475